Ask AI
SERDs for Advanced Breast Cancer

CE / CME

Clinical Evidence for Next-Generation Approaches Targeting the Estrogen Receptor

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Released: May 30, 2025

Expiration: December 25, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Case Description: 



  • 59-yr-old postmenopausal woman was diagnosed with de novo metastatic with ER+/HER2- breast cancer in 2020

  • At that time, she initiated first-line therapy with a CDK4/6i (palbociclib) + letrozole

    • NGS on bone biopsy showed no specific actionable mutations





  • Disease has been well controlled for the past 5 yr, but the most recent restaging suggests asymptomatic progression in bone

  • Current NGS by ctDNA shows ESR1 D538G mutation but no PIK3CA/ AKT/PTEN pathway alteration(s)

    • No germline BRCA1/2 mutation



At this time, which of the following would you recommend as the best next step for this patient?

2.

In the phase III EMBER-3 trial for patients with ER+/HER2- ABC, which of the following was reported with imlunestrant ± abemaciclib vs SoC ET?

3.

Case Description:



  • 62-yr-old postmenopausal woman has achieved stable disease on
    first-line letrozole plus ribociclib for ER+/HER2- MBC for the past yr

  • She enrolled in the first step of the phase III SERENA-6 trial, which involves ctDNA surveillance every 2-3 cycles for ESR1 mutation–positive disease

  • ctDNA analysis reveals the presence of an ESR1 mutation in the absence of clinical progression, and she is randomized to camizestrant + abemaciclib

  • Now, you are in a morning huddle with your clinical team discussing patient care

At this time, what toxicities specific to camizestrant will you review with your clinical team?